The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
CAR-T CELLS (I) – (II)
Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease of patients suffering from Refractory/ Resistant Hematologic malignancies. This success has now lead the FDA and EMA to approve rapidly these innovative cellular drugs.
Based on these unexpected and impressive results, the world of cellular immunotherapy offers new perspectives. The two sessions dedicated to CAR expressing T or NK [Dr Mattias Carlsen] autologous or allogeneic cells [Dr Laurent Poirot] will cover a range of topics from research [Dr Emmanuel Donnadieu (imaging), Dr Suman Mitra (cytokines’ use improvement), Dr Marco Ruella (understanding escape)] to the clinic [Dr Jordan Gauthier, Pr André Baruchel] through drug production [Dr Isabelle Rivière, Dr Georg Rauser].
It will also give another view of the remarkable potential of this approach in solid tumors [Pr Stephan Depil]. It will explain how European Bone Marrow Transplantation registry may help in better understanding Immune Effector Cells derived therapeutics [Pr Christian Chabannon].
Mix and exchanges of people from different backgrounds (academic, scientists, pharmacists, clinicians, private companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.
IPS & MSCS
This session will gather experts in the development of IPS and MSCs cell-based therapies to the clinic. IPs will be discussed as source of hematopoietic cells [Nico Lachmann] or tissues [John de Vos] and MCSs in the context of auto or allo-therapies [Jens Kastrup] or in rheumatoid diseases [Christian Jorgensen].
Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.
REGULATORY & BIO-PROD PLATFORMS
This session will give us an overview of the regulatory guidelines defined for ATMP and border-line products [Nicolas Ferry], a review of the last months of work of the ANSM gate dedicated to innovative products [Camille Schurtz] as well as the European view of ATMP deployment in hematological malignancies [Christian Chabannon]. Also, difficulties and success in the production of such products will be tell with concrete examples by people facing production and regulatory constraints [Hélène Negre-Trebeden; Anne Fialaire-Legendre; Stephan Roux].
Thursday, October 14th
Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR
Welcome words from the urban community’s President
Welcome words from the Region’s President
Welcome words from the Pôle des Microtechniques’ President
Welcome words from the National French Blood Center’s President
Chairmen: Christophe Ferrand and Marina Deschamps, RIGHT institute, Besançon, FR
Isabelle Rivière, Memorial Sloan Kettering, NYC, USA
Georg Rauser, Miltenyi Biomedicine, DE
Emmanuel Donnadieu, INSERM, Institut Cochin, Paris, FR
Stephane Depil, Centre Léon Bérard, Lyon, FR
Julien Valton, Cellectis, Paris, FR
Chairmen: Marie José Stasia, Grenoble Alpes University, Grenoble, FR
and Sylvain Perruche, RIGHT Institute, Besançon, FR
Christian Jorgensen, INSERM U1183, IRMB, Montpellier, FR
Philippe Henon, Cellprothera, FR
John de Vos, INSERM U1183, CHU Montpellier, FR
Nico Lachmann, Hannover Medical School, Hannover, DE
Camille Fialin , Treefrog Therapeutics , FR
Friday, October 15th
Chairmen: Mathieu Guerriaud, CREDIMI, Dijon, FR
and Nicolas Ferry, Paris, FR
Nicolas Ferry, Paris, FR
Hélène Negre-Trebeden, Servier, Paris, FR
Camille SCHURTZ, ANSM, FR
10:30 : PRESENTATION OF THE EFS PHARMACEUTICAL ESTABLISHMENT AND LOCAL SPECIFICITIES
Anne Fialaire-Legendre, EFS, FR & Stephan Roux, EFS BFC, FR
Christian Chabannon, Institut Paoli-Calmettes, Marseille, FR
Chairmen: André Baruchel , Hôpital Robert-Debré, Paris, FR
and Suman Mitra, INSERM, Lille, FR
Marco Ruella, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA
Suman Mitra, INSERM, Lille, FR
André Baruchel, Hôpital Robert-Debré, Paris, FR
Jordan Gauthier, Fred Hutchinson Cancer Research Center , University of Washington, Seattle, WA, USA
Marcello Maresca, AstraZeneca, Sweden, SW
Experienced Professor with a demonstrated history of working in the higher education industry. Skilled in Regenerative Medicine, Molecular Oncology, Hematology, Biotechnology, and Stem Cells. Strong healthcare services professional graduated from University Paris Descartes - School of Medicine.
En savoir +Nicolas Ferry is a M.D., Ph.D. His initial training in research was in endocrinology and pharmacology where he studies the regulation alpha adrenergic receptors in liver and blood platelets. During a post-doctoral stay at the Pasteur Institute in 1990, he...
En savoir +Jordan Gauthier is an Assistant Professor at the Fred Hutchinson Cancer Research Center (FHCRC) and the University of Washington in Seattle, WA. He was the first physician to be awarded the FHCRC Immunotherapy Integrated Research Center Fellowship Award. An expert...
En savoir +Pharmacien et ancien interne des hôpitaux de Paris, Anne Fialaire-Legendre a été nommée à l’Agence Française du Sang en 2003 pour participer activement à la réforme de la transfusion sanguine. Elle est à l’origine de la création du réseau français...
En savoir +Marie José Stasia is an Associate professor (Pharm D, PhD) at the University Grenoble Alpes and an hospital partitionner in charge of the unique national referent laboratory for the Chronic Granulomatous Disease (CGD) diagnostic (phenotype and genotype) at the Centre...
En savoir +Mathieu Guerriaud is a Doctor of Pharmacy (PharmD) and a Doctor of Science (PhD). He is an associate professor in pharmaceutical law, teaching at the Faculty of Health Sciences while working as a researcher in a law laboratory: the CREDIMI....
En savoir +Christian Chabannon is the Qualified Person for the Centre de Thérapie Cellulaire that associates the Cell Collection Facility and the Cell Processing Facility at Institut Paoli-Calmettes Comprehensive Cancer Center, in Marseille, France.
En savoir +Dr. Emmanuel Donnadieu leads the team ‘Cancer and immune response’ at the Cochin Institute, INSERM, in Paris. Working in the field of Immunology for more than 15 years, he has accumulated a thorough experience in cell signalling and cellular imaging...
En savoir +- 1968 : Thèse de Médecine, Paris - 1970 ; Certificat d’Etudes Spéciales en Hématologie - 1970- 1974 : Assistant bi-appartenant, Hôpitaux de Paris/Université Paris VII, UER d’Hématologie - 1974-1978 :Chef de Service –adjoint, Service d’Immuno-Hématologie, Hôpital Lariboisière-AP/HP, Paris -...
En savoir +Holding a PhD in Oncology and a MBA in Biotech Management, Camille has been working in the field of cell and gene therapy for the past 5 years. She successively worked for Merck Millipore, Pfizer and Miltenyi Biotec before joining...
En savoir +Hanover Medical School Clinic for Paediatric Pneumology, Allergology and Neonatology
En savoir +Prof. Stéphane Depil, M.D., Ph.D., is onco-hematologist at Léon Bérard Cancer Center, group leader at Cancer Research Center of Lyon, and adjunct Professor at University Claude Bernard Lyon 1, France. He was also Visiting Professor at King’s College London. He...
En savoir +Christian Jorgensen is specialized in translational research for a better application of stem cells in immunology and rheumatology. He gathers scientists and clinicians on regenerative medicine and innovative immunotherapies. He has extensively published, has a strong track record for competitive...
En savoir +Marcello Maresca is an Associate Director at AstraZeneca where he is currently leading the Precise Genome Editing team. In his role he supervises the strategy for the generation of advanced cellular and animal models of disease and for Therapeutic Genome...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +I studied Pharmacy in Tuebingen, did my PhD in Immunology, joined Miltenyi in 2003. There I started in the R&D Department, then changed to the Clinical Development department and now I´m Group Leader for T cell Immunotherapy in the Miltenyi...
En savoir +After an initial training in clinical hematology, I worked in an hematology intensive care and bone transplantation unit, then as a clinical consultant at the Besançon University hospital, France until 2009. I headed an immunogenetics laboratory from 1994 to 2004...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...
En savoir +